New research reveals that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional diet and exercise plans.
Findings released in a major medical journal shows that while overweight individuals can lose a large proportion of their total mass while using the jabs, the weight is regained at an estimated rate of 0.8 kg per month once they quit.
"People buying these treatments must be aware of the danger of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
This pace of regain means a reversion to starting weight in about 18 months.
Analyzing Therapies
The analysis, which reviewed dozens of trials involving thousands of participants, contrasted the effects of these new drugs with older methods.
The team emphasize that individuals who shed pounds through lifestyle changes alone usually see a slower creep back—around 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Nutrition scientists suggest the mechanism of the injections explains the amplified weight return.
The injections copy a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
Health authorities suggest the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals contend that, due to the high risk of weight regain, the therapy might need to be ongoing.
This perspective is echoed by drug manufacturers, who say that the findings "highlight the persistent character of excess weight," akin to managing conditions like hypertension.
Patient Experiences
Individuals who have come off the jabs explain a powerful resurgence of cravings.
"It felt as if something flipping and I was suddenly starving," recalled a patient.
The struggle is exacerbated if individuals have not established lasting dietary or behavioural changes during therapy.
Growing Use
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits relies on combined behavioural changes.
